PDF herunterladen
CC BY-NC-ND 4.0 · Int Arch Otorhinolaryngol 2018; 22(02): 152-156
DOI: 10.1055/s-0037-1605596
Original Research
Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

The Role of the Level of Interleukin-33 in the Therapeutic Outcomes of Immunotherapy in Patients with Allergic Rhinitis

Wail Fayez Nasr
1   Department of Otorhinolaryngology and Head and Neck Surgery, Zagazig University Faculty of Human Medicine, Zagazig, El Sharkeya, Egypt
,
Samir Sorour Sorour
1   Department of Otorhinolaryngology and Head and Neck Surgery, Zagazig University Faculty of Human Medicine, Zagazig, El Sharkeya, Egypt
,
Atef Taha El Bahrawy
1   Department of Otorhinolaryngology and Head and Neck Surgery, Zagazig University Faculty of Human Medicine, Zagazig, El Sharkeya, Egypt
,
Ghada Samir Boghdadi
2   Department of Microbiology and Immunology, Zagazig University Faculty of Human Medicine, Zagazig, El Sharkeya, Egypt
,
Alia A El Shahaway
2   Department of Microbiology and Immunology, Zagazig University Faculty of Human Medicine, Zagazig, El Sharkeya, Egypt
› Institutsangaben
Weitere Informationen

Publikationsverlauf

19. Oktober 2016

03. Juli 2017

Publikationsdatum:
28. August 2017 (online)

   Lizenzen und Reprints

Abstract

Introduction Allergic rhinitis (AR) affects up to 40% of the population and results in nasal itching, congestion, sneezing, and clear rhinorrhea.

Objectives This study aimed to evaluate the changes in the clinical symptoms and in the level of serum interleukin (IL)-33 before and after pollen immunotherapy (IT) in patients with AR.

Methods The total symptom score and the levels of total immunoglobulin E (IgE) and IL-33 were determined in the serum of 10 non-allergic healthy controls and 45 patients with AR who were equally divided into 3 groups: GI (patients did not receive IT), GII (patients had received IT for 6 months) and GIII (patients had received IT for 2 years).

Results There was a significantly higher concentration of IgE and IL-33 in the serum of patients with AR than in that of non-allergic patients. Furthermore, serum level of IL-33 decreased significantly after pollen IT. But, there was no significant reduction in the serum level of IL-33 between GII and GIII patients.

Conclusion Our results show a clinical improvement associated with a decrease in serum level of IL-33 after pollen IT.

Keywords

immunotherapy - allergic rhinitis - helper T cells - allergen immunotherapy
 

  • References

  • 1 Uzzaman A, Story R. Chapter 5: Allergic rhinitis. Allergy Asthma Proc 2012; 33 (Suppl. 01) S15-S18
    CrossrefPubMedGoogle Scholar
  • 2 Cox L, Wallace D. Specific allergy immunotherapy for allergic rhinitis: subcutaneous and sublingual. Immunol Allergy Clin North Am 2011; 31 (03) 561-599
    CrossrefPubMedGoogle Scholar
  • 3 Asaka D, Yoshikawa M, Nakayama T, Yoshimura T, Moriyama H, Otori N. Elevated levels of interleukin-33 in the nasal secretions of patients with allergic rhinitis. Int Arch Allergy Immunol 2012; 158 (Suppl. 01) 47-50
    CrossrefPubMedGoogle Scholar
  • 4 Glück J, Rymarczyk B, Rogala B. Serum IL-33 but not ST2 level is elevated in intermittent allergic rhinitis and is a marker of the disease severity. Inflamm Res 2012; 61 (06) 547-550
    CrossrefPubMedGoogle Scholar
  • 5 Schatz M, Meltzer EO, Nathan R. , et al. Psychometric validation of the rhinitis control assessment test: a brief patient-completed instrument for evaluating rhinitis symptom control. Ann Allergy Asthma Immunol 2010; 104 (02) 118-124
    CrossrefPubMedGoogle Scholar
  • 6 Passalacqua G, Durham SR. ; Global Allergy and Asthma European Network. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007; 119 (04) 881-891
    CrossrefPubMedGoogle Scholar
  • 7 Bousquet J, Khaltaev N, Cruz AA. , et al; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl. 86) 8-160
    CrossrefPubMedGoogle Scholar
  • 8 Shaaban R, Zureik M, Soussan D. , et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008; 372 (9643): 1049-1057
    CrossrefPubMedGoogle Scholar
  • 9 Walker SM, Durham SR, Till SJ. , et al; British Society for Allergy and Clinical Immunology. Immunotherapy for allergic rhinitis. Clin Exp Allergy 2011; 41 (09) 1177-1200
    CrossrefPubMedGoogle Scholar
  • 10 Durham SR, Emminger W, Kapp A. , et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129 (03) 717-725.e5
    CrossrefPubMedGoogle Scholar
  • 11 Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 2010; 40 (02) 200-208
    CrossrefPubMedGoogle Scholar
  • 12 Boghdadi G, Marei A, Ali A, Lotfy G, Abdulfattah M, Sorour S. Immunological markers in allergic rhinitis patients treated with date palm immunotherapy. Inflamm Res 2012; 61 (07) 719-724
    CrossrefPubMedGoogle Scholar
  • 13 Kamekura S. Expression of IL-33 in the nasal epithelium of patients with AR and production of cytokines/ chemokines. Clin Exp Allergy 2012; 80: 531-538
    Google Scholar
  • 14 Haenuki Y, Matsushita K, Futatsugi-Yumikura S. , et al. A critical role of IL-33 in experimental allergic rhinitis. J Allergy Clin Immunol 2012; 130 (01) 184-94.e11
    CrossrefPubMedGoogle Scholar
  • 15 Du Y, Luo Y, Yang C, Liu J, Wan J, Wang K. [Discussion IL-33 and its receptor ST2 associated with the pathogenesis of allergic rhinitis]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2015; 29 (09) 811-814
    PubMedGoogle Scholar
  • 16 Yoshimoto T, Matsushita K. Innate-type and acquired-type allergy regulated by IL-33. Allergol Int 2014; 63 (Suppl. 01) 3-11
    PubMedGoogle Scholar
  • 17 Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P. Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther 2015; 354 (01) 24-31
    CrossrefPubMedGoogle Scholar
  • 18 Dretzke J, Meadows A, Novielli N, Huissoon A, Fry-Smith A, Meads C. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol 2013; 131 (05) 1361-1366
    CrossrefPubMedGoogle Scholar